Thursday, October 09, 2014

Triazole-based compound as the candidate to develop a novel medicines to treat toxoplasmosis

2014 Oct 6. pii: AAC.03832-14. [Epub ahead of print]
This letter reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible anti-parasitic effects at non-toxic concentrations for the host cells, with experimentally determined IC50 value at least thirty time better than the one of known chemotherapeutic sulfadiazine. Purine nucleoside phosphorylase was defined as probable target for anti-Toxoplasma activity of tested compound. These results provide the foundation for the future work to develop a new class of medicines to better treat toxoplasmosis.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.
[PubMed - as supplied by publisher]

No comments: